Dara Vira Azma company

This letter serves to formally certify that the MICROBNET™ software—a clinical microbiology reporting and decision-support system—was developed by Dara Vira Azma Company under the scientific supervision of Dr. Dariush Shokri, PhD, and has been in active diagnostic use at Nobel Medical Laboratory, Isfahan, for the past six months. During this period, it has processed and interpreted over 6,000 clinical cases.

Following a comprehensive internal evaluation and continuous daily use, the platform’s performance has been outstanding in the following key areas:

• Accuracy & Reliability: Approximately 90% reduction in reporting errors.
• Operational Efficiency: Turnaround time improved by an average of 50%.
• User Experience: Intuitive interface with rapid adoption by laboratory personnel.
• Regulatory Compliance: Full alignment with CLSI and ISO 15189 standards.
• Data Security: Robust protection of patient information and audit trails.

The implementation of MICROBNET™ has significantly optimized our laboratory workflow, reduced manual errors, and accelerated diagnostic reporting and supporting antimicrobial stewardship and the global effort against antimicrobial resistance (AMR). Its performance has been reviewed and unanimously endorsed by our IT department, clinical microbiologists, and laboratory management.

We commend Dr. Shokri and the development team for their innovative contribution to diagnostic science. Nobel Laboratory (Arad Padideh Sanjesh Co.) hereby expresses complete satisfaction with MICROBNET™ and confirms that it has substantially elevated the quality, precision, and reliability of our clinical microbiology services.

I have had the professional privilege of knowing Dr. Dariush Shokri for over 15 years, both as a colleague and through his significant contributions to clinical microbiology.

In recent months, I have regularly used the MICROBNET™ platform developed by Dr. Shokri in my infectious disease practice at Milad Hospital. The system provides clear, CLSI-aligned interpretations of microbiology reports, offering practical assistance in:

• Selecting appropriate antibiotics based on susceptibility patterns
• Identifying resistant organisms and guiding targeted therapy
• Improving accuracy and efficiency in clinical decision-making
• The tool has proven valuable in managing complex antimicrobial resistance cases.

Beyond this innovation, I have always known Dr. Shokri as a dedicated scientist and a forward-thinking professional with a strong commitment to advancing laboratory medicine and public health.

I am writing to both verify the clinical value of the MICROBNET™ platform and to provide my personal recommendation for its developer, Dr. Dariush Shokri, whom I have professionally collaborated with for over ten years.

I hereby confirm that I have reviewed and utilized the microbiology interpretation reports generated by the MICROBNET™ platform. As a Pediatric Infectious Diseases specialist, I recognize the critical importance of accuracy, standardization, and rapid interpretation in microbiological diagnostics—especially in children, where delays or inconsistencies can significantly affect clinical outcomes.

MICROBNET™ provides highly consistent, reproducible, and clinically meaningful interpretations, reducing observer-dependent variability and improving diagnostic confidence.

The platform’s structured reporting also contributes to infection-control programs and supports antimicrobial resistance (AMR) monitoring, which is increasingly essential in pediatric healthcare due to rising resistance patterns and limited therapeutic options for children.

Throughout our decade-long professional relationship, I have found Dr. Shokri to be an exceptionally dedicated scientist and innovator. His deep expertise in clinical microbiology has been invaluable in numerous complex cases.

This letter confirms that I, Dr. Hamed Jahangiri, Urology Specialist, have reviewed and utilized the microbiology reports generated by the MICROBNET™ platform developed by Dr. Dariush Shokri.

MICROBNET™ has demonstrated significant clinical value in the management of urinary tract infections (UTIs), particularly through its:

• CLSI-aligned interpretation of AST results and Tier-based antibiotic prioritization
• Automated detection of intrinsic resistance and inappropriate drug-organism combinations
• Clear interpretive comments that assist in selecting the most effective therapy
• Accurate and standardized reporting of urine culture and direct microscopic findings

As a practicing urologist with extensive experience in managing complex urinary tract infections, I am pleased to verify the exceptional clinical utility of the MICROBNET™ platform developed by Dr. Dariush Shokri.

In my daily practice, I routinely rely on MICROBNET™ reports for their precision in several key areas:

• Advanced Urine Culture Analysis that goes beyond basic reporting to provide clinically actionable insights
• Intelligent Antibiotic Stratification that categorizes treatment options by efficacy and safety profile
• Resistance Pattern Recognition that alerts to potential therapeutic failures before they occur
• Unified Diagnostic Reporting that integrates multiple data points into clear clinical guidance

What distinguishes this platform is its ability to transform complex laboratory data into practical treatment roadmaps – particularly valuable in managing recurrent UTIs and complicated nephrological cases where antibiotic selection becomes critical.

My professional association with Dr. Shokri spans several years, during which I've witnessed his uncommon dedication to bridging diagnostic science with clinical practice. His innovative approach in developing MICROBNET™ demonstrates precisely the kind of forward-thinking medical technology that advances patient care.

I am writing to provide my professional assessment of the MICROBNET™ platform and to endorse its creator, Dr. Dariush Shokri, with whom I have collaborated closely for over a decade in the field of clinical microbiology and infectious diseases.

As an infectious disease specialist, I have consistently relied on MICROBNET™ for its sophisticated analytical capabilities, which include:

• Predictive Resistance Profiling that anticipates emerging antimicrobial resistance trends
• Evidence-Based Therapeutic Pathways tailored to patient-specific clinical scenarios
• Integrated Diagnostic-Treatment Algorithms that bridge laboratory findings with therapeutic decisions
• Real-Time Antimicrobial Stewardship Support enabling proactive intervention in complex cases

The platform has redefined how we approach microbiological diagnostics, particularly for cases involving multidrug-resistant organisms and healthcare-associated infections. Its ability to synthesize complex data into clinically actionable insights has enhanced both patient outcomes and antimicrobial stewardship efforts.

My professional relationship with Dr. Shokri spans more than ten years, during which I have witnessed his extraordinary dedication to advancing diagnostic medicine. His development of MICROBNET™ exemplifies his unique talent for identifying clinical needs and transforming them into innovative technological solutions. His work has consistently demonstrated remarkable foresight in addressing the growing challenge of antimicrobial resistance.